Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

Chief Financial Officer

SVP and General Counsel

Chief People Officer

Principal Accounting Officer

President

Chief Commercial Officer, MRD

CEO and Chairman

Chief Commercial Ofc Imm Med

Chief Scientific Officer

Chief Operating Officer

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals. It also provides clonoSEQ, a clinical diagnostic product for the detection and monitoring of minimal residual disease in patients with multiple myeloma, B cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia, as well as available as a CLIA-validated laboratory developed test for patients with other lymphoid cancers. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer and autoimmune disorders. It offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of ...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-03-12	Premium	acquired	Premium	Premium	Premium	-
2024-03-05	Premium	sold	Premium	Premium	Premium	Chief Financial Officer
2024-03-05	Premium	sold	Premium	Premium	Premium	SVP and General Counsel
2024-03-05	Premium	sold	Premium	Premium	Premium	Chief People Officer
2024-03-05	Premium	sold	Premium	Premium	Premium	Principal Accounting Officer
2024-03-05	Premium	sold	Premium	Premium	Premium	President
2024-03-05	Premium	sold	Premium	Premium	Premium	Chief Commercial Officer, MRD
2024-03-05	Premium	sold	Premium	Premium	Premium	CEO and Chairman
2024-03-05	Premium	sold	Premium	Premium	Premium	Chief Commercial Ofc Imm Med
2024-03-04	Premium	acquired	Premium	Premium	Premium	Chief People Officer
2024-03-04	Premium	acquired	Premium	Premium	Premium	SVP and General Counsel
2024-03-04	Premium	acquired	Premium	Premium	Premium	-
2024-03-04	Premium	acquired	Premium	Premium	Premium	Chief Financial Officer
2024-03-04	Premium	acquired	Premium	Premium	Premium	CEO and Chairman
2024-03-04	Premium	acquired	Premium	Premium	Premium	-
2024-03-04	Premium	acquired	Premium	Premium	Premium	Chief Commercial Ofc Imm Med
2024-03-04	Premium	acquired	Premium	Premium	Premium	-
2024-03-04	Premium	acquired	Premium	Premium	Premium	Principal Accounting Officer
2024-03-04	Premium	acquired	Premium	Premium	Premium	Chief Scientific Officer
2024-03-04	Premium	acquired	Premium	Premium	Premium	Chief Commercial Officer, MRD
2024-03-04	Premium	acquired	Premium	Premium	Premium	-
2024-03-04	Premium	acquired	Premium	Premium	Premium	President
2024-03-04	Premium	acquired	Premium	Premium	Premium	-
2023-12-13	Premium	acquired	Premium	Premium	Premium	-
2023-11-16	Premium	sold	Premium	Premium	Premium	Principal Accounting Officer

ADPT - Adaptive Biotechnologies Corp Stock Price, Fair Value and News

Latest Insider Trading transactions for ADPT